ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma

Grant

Date/time Interval

  • April 16, 2018 - April 15, 2022
  • Total Award Amount

  • 23000.00
  • Direct Costs

  • 17692.00
  • Sponsor Award Id